Last reviewed · How we verify
NCT04393194
The Effect of Intra-vaginal Conjugated Estrogen Cream on Ring Pessary Use for Pelvic Organ Prolapse
Phase 4 trial testing Vaginal Cream with Applicator [Dose Form] in Pelvic Floor Prolapse in 420 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 420 |
| Start date | 24 May 2020 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 September 2022 |
Drugs / interventions tested
- Vaginal Cream with Applicator [Dose Form] — full drug profile →
Conditions studied
- Pelvic Floor Prolapse — all drugs for Pelvic Floor Prolapse →
Sponsor
Peking Union Medical College Hospital
Who can join
Eligibility, female only, with Pelvic Floor Prolapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this two-arm randomized clinical trial is to determine if in women desiring use of a pessary for pelvic organ prolapse (POP) and are successfully fit, if 1-year use and patient impression of improvement is superior in women using vaginal estrogen cream versus those using a vaginal placebo cream.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of intravaginal conjugated oestrogen on pessary continuation for pelvic organ prolapse: multicentre, randomised, double blind, placebo controlled trial.
Zhou Y, Yin R, Zhang Y, Wang X, et al · · 2025 · cited 3× · PMID 40578851 · DOI 10.1136/bmj-2025-084418
Verify or expand the search:
- PubMed search for NCT04393194
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pelvic Floor Prolapse
Currently open trials in the same condition.
- NCT04547816 — Efficacy of Conservative Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse · Phase 3 · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04393194 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 19 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04393194.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing